New Technology, Old Standards: Disparate Activated Clotting Time Measurements by the Hemochron Jr Compared with the Standard Hemochron

Annals of Thoracic Surgery

Volumn 77, Issue 3, 2004, Pages 973-976

  Aylsworth, Christopher L ^a,b   Stefan, Faith ^a   Woitas, Karl ^a   Rieger, Randall H ^a   LeBoutillier III, Martin ^a   DiSesa, Verdi J ^a  

^a WEST CHESTER UNIVERSITY   (United States)

^b The Chester County Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; PROTAMINE;

ANALYSIS OF VARIANCE; ARTICLE; ASSAY; BLOOD CLOTTING TIME; BLOOD SAMPLING; CARDIOPULMONARY BYPASS; CARDIOVASCULAR SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; COVARIANCE; DOSE RESPONSE; DRUG MEGADOSE; HEPARINIZATION; HUMAN; PRIORITY JOURNAL; STATISTICAL MODEL;

EID: 1442275653     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4975(03)01660-6     Document Type: Article

References (17)

1. Verska J.J. Control of heparinization by activated clotting time during bypass with improved postoperative hemostasis. Ann Thorac Surg. 24:1977;170-173.
2. Young J.A., Kisker C.T., Doty D.B. Adequate anticoagulation during cardiopulmonary bypass determined by activated clotting time and the appearance of fibrin monomer. Ann Thorac Surg. 26:1978;231-240.
3. Niles S.D., Sutton R.G., Ploessl J., Pennell B. Correlation of ACT as measured with three commercially available devices with circulating heparin level during cardiac surgery. J Extra Corpor Technol. 27:1995;197-200.
4. Mabry C.D., Thompson B.W., Read T.C., Campbell G.S. Activated clotting time monitoring of intraoperative heparinization our experience and comparison of two techniques. Surgery. 90:1981;889-895.
5. Esposito R.A., Culliford A.T., Colvin S.B., Thomas S.J., Lackner H., Spencer F.C. The role of the activated clotting time in heparin administration and neutralization for cardiopulmonary bypass. J Thorac Cardiovasc Surg. 85:1983;174-185.
6. Akl B.F., Vargas G.M., Neal J., Robillard J., Kelly P. Clinical experience with the activated clotting time for the control of heparin and protamine therapy during cardiopulmonary bypass. J Thorac Cardiovasc Surg. 79:1980;97-102.
7. Lefemine A.A., Lewis M. Activated clotting time for control of anticoagulation during surgery. Am Surg. 51:1985;274-278.
8. Gravlee G.P., Rogers A.T., Dudas L.M., et al. Heparin management protocol for cardiopulmonary bypass influences postoperative heparin rebound but not bleeding. Anesthesiology. 76:1992;393-401.
9. Feindt P., Seyfert U.T., Volkmer I., Straub U., Gams E. Celite and kaolin produce differing activated clotting times during cardiopulmonary bypass under aprotinin therapy. Thorac Cardiovasc Surg. 42:1994;218-221.
10. Huyzen R.J., van Oeveren W., Wei F., Stellingwerf P., Boonstra P.W., Gu Y.J. In vitro effect of hemodilution on activated clotting time and high-dose thrombin time during cardiopulmonary bypass. Ann Thorac Surg. 62:1996;533-537.
11. Malviya S. Monitoring and management of anticoagulation in children requiring extracorporeal circulation. Semin Thromb Hemost. 23:1997;563-567.
12. Despotis G.J., Joist J.H. Anticoagulation and anticoagulation reversal with cardiac surgery involving cardiopulmonary bypass an update. J Cardiothorac Vasc Anesth. 13:(4 Suppl 1):1999;18-29.
13. Bland J.M., Altman D.G. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1:1986;307-310.
14. Bland J.M., Altman D.G. Measuring agreement in method comparison studies. Stat Methods Med Res. 8:1999;135-160.
15. Laird N.M., Ware J.H. Random effects models for longitudinal data. Biometrics. 38:1982;963-974.
16. Liang K.Y., Zeger S.L. Longitudinal data analysis using generalized linear models. Biometrika. 73:1986;13-22.
17. Little R.C., Milliken G.A., Stroup W.W., Wolfinger D.W. SAS system for mixed models. 1996;SAS Institute, Inc. Cary, NC. 663.